Recommendations from the NM Medical Advisory Team include, but are not limited to:

1. Bamlanivimab should be distributed to centers with the capacity for intravenous administration and monitoring of outpatients who meet criteria of administration under the FDA Emergency Use Authorization (EUA).
2. Bamlanivimab is intended for outpatient treatment of mild to moderate coronavirus disease 2019 (COVID- 19) in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg (88.18 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
3. Bamlanivimab should be given as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.
4. Bamlanivimabt is not authorized for use in patients who are hospitalized or require oxygen therapy from COVID-19 (new or increase from baseline), or mechanical ventilation.

Download this resource